[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"serous-cystadenoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:serous-cystadenoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100641512","assessment-of-the-usefulness-of-smi-superb-vascular-imaging-for-the-characterisation-of-pancreatic-cystic-tumours-imakyst-100641512",false,"NCT07657884","Assessment of the Usefulness of SMI (Superb Vascular Imaging) for the Characterisation of Pancreatic Cystic Tumours (IMAKYST)","IMAKYST","Inclusion Criteria:\n\n* Patient referred for confocal microscopy (nCLE) assessment of a pancreatic cyst of unknown origin\n* Patient with a cyst measuring more than 15 mm in diameter and at least one cyst cavity measuring ≥ 5 mm (to allow nCLE to be performed)\n* Patient registered with or covered by the National Health Service\n* French-speaking patient who has signed an informed consent form\n\nExclusion Criteria:\n\n* Patient with calcifying chronic pancreatitis\n* Presence of a communication with the main pancreatic duct on MRI or endoscopic ultrasound\n* Patient whose lesion meets criteria for malignancy (tissue mass, metastases, ascites, vascular infiltration)\n* Patient with a contraindication to endoscopic ultrasound-guided puncture (haemostatic disorder)\n* Patient with a known allergy to fluorescein (used in nCLE)\n* Pregnant woman\n* Patient under legal guardianship: adults under guardianship, curatorship or other legal protection, or deprived of their liberty by judicial or administrative order\n* Hospitalised patient without consent","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","A cystic lesion is an abnormal cavity formed within tissue or an organ, which may contain a liquid, semi-solid or gaseous substance.\n\nThere are different types of pancreatic cystic lesions: lesions that may become cancerous and completely benign lesions that do not require monitoring, such as serous cystadenomas (SCs) and pseudocysts.\n\nDiagnostic difficulties mean that one in three patients with a SC undergoes unnecessary surgery with significant morbidity and mortality (risk of death). Currently, needle-based confocal laser endomicroscopy (nCLE) is the gold standard technique for the diagnosis of SC.\n\nSC is a lesion characterised by an extensive network of small blood vessels present in all the cyst walls and throughout the cyst's peripheral capsule. SMI (Superb Vascular Imaging) is a new ultrasound mode that improves the visibility of blood flow in the vessels without the injection of contrast medium (a diagnostic agent used for certain medical imaging examinations, most often administered intravenously), unlike nCLE.\n\nThe Mermoz Endoscopy Centre will be equipped with an ultrasound console enabling SMI to be performed during an echoendoscopy examination. This technology is now available on the new EUS Aplio i800 console (Canon-Olympus), which is CE marked.\n\nTo date, no data has been published on the potential of SMI to characterise and diagnose CS. This is why this clinical investigation is being conducted.",[26],"Serous Cystadenoma",[28,29],"SMI","serous cystadenoma","RECRUITING","2026-06-13",{"date":33,"type":34},"2026-06-18","ACTUAL",{"date":36,"type":34},"2026-05-15",{"date":38,"type":20},"2027-11-30",{"name":40,"class":41},"GCS Ramsay Santé pour l'Enseignement et la Recherche","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":5},"100628610","management-of-pancreatic-cystic-lesions-using-artificial-intelligence-based-on-eus-and-multimodal-data-100628610","NCT07463872","Management of Pancreatic Cystic Lesions Using Artificial Intelligence Based on EUS and Multimodal Data","A Multimodal Artificial Intelligence Model for Subtyping Diagnosis and Clinical Management of Pancreatic Cystic Lesions Based on Endoscopic Ultrasound and Clinical Information","Inclusion criteria:\n\n* Patients whose EUS results indicates pancreatic cystic or cystoid lesions;\n* Mucinous lesions: including mucinous cystic neoplasm (MCN), intraductal papillary mucinous neoplasm (IPMN);\n* Non-mucinous lesions: including pancreatic pseudocyst, serous cystic neoplasm (SCN), cystic neuroendocrine tumor (cNET).\n\nExclusion criteria:\n\n* Patients whose age is less than 18 years old;\n* Patients who have undergone pancreatic surgery before the EUS examination;\n* Patients who have received chemotherapy and radiotherapy for pancreatic tumors before the EUS examination;\n* Pathological results indicate that pancreatic lesions are metastatic lesions from other sites;\n* Patients whose EUS images or reports are missing;\n* EUS image quality does not meet the requirements for review, such as blurry imaging or containing artifacts, biopsy needles, measuring scales, or other additional annotations that are not part of the original EUS image;\n* Patients whose final diagnosis is unclear.",{"count":51,"type":20},500,"OBSERVATIONAL","The primary objective is to construct a multimodal AI model (Cyst-AI) based on EUS images and clinical data such as imaging features(CT or MRI) and laboratory tests to assist endoscopists in the diagnosis of pancreatic cystic lesions(PCLs), mainly differentiating mucinous from non-mucinous lesions.\n\nThe secondary objective is to evaluate the model's effectiveness in risk stratification and clinical management for patients with PCLs.",[55,56,57,58,26,59],"Pancreatic Cystic Lesion","Mucinous Cystadenoma of Pancreas","Intraductal Papillary Mucinous Neoplasm of Pancreas","Pseudocyst Pancreas","Neuroendocrine Tumors, NET",[61,62,63,64,65,66,67],"pancreatic cystic lesions","artificial intelligence","endoscopic ultrasound","multimodal","differentiation","risk stratification","clinical management","2026-03-05",{"date":70,"type":34},"2026-03-11",{"date":72,"type":34},"2025-01-01",{"date":74,"type":20},"2026-06",{"name":76,"class":41},"Huazhong University of Science and Technology"]